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a b s t r a c t 
Background: Four-factor prothrombin complex concentrates (4F-PCCs) have been approved for urgent vi- 
tamin K antagonist reversal in Western countries for many years. Ethnicity and genetic variations between 
populations may inﬂuence the pharmacokinetic proﬁle of 4F-PCC treatments. 
Objective: To report plasma levels of vitamin K-dependent coagulation factors and proteins C and S in 
Japanese patients following administration of a 4F-PCC approved recently in Japan. 
Methods: This was a subanalysis of a prospective, open-label, Phase IIIb study in Japanese patients re- 
quiring rapid vitamin K antagonist reversal owing to major bleeding (n = 6) or need for urgent surgery 
(n = 5). International normalized ratio and plasma levels of factors II, VII, IX, and X, and proteins C and S 
were measured before PCC infusion and at speciﬁc time points for the next 24 hours. Adverse events and 
serious adverse events were recorded up to Day 14 and 45, respectively. 
Results: Rapid increases in plasma concentrations 30 minutes following 4F-PCC infusion were seen for all 
factors and proteins C and S, with median concentrations compared with baseline increasing by ≥100% 
and 70% in the bleeding and surgical groups, respectively. A concurrent decrease in international nor- 
malized ratio was observed. Plasma levels for each factor and protein remained within physiologic levels 
throughout the assessment period. No relationship between thromboembolic events and elevated plasma 
levels was identiﬁed. 
Conclusions: Administration of 4F-PCC in Japanese patients receiving vitamin K antagonist anticoagulation 
therapy resulted in rapid and sustained increases in plasma levels and was well tolerated, indicating that 
this treatment is effective for the urgent reversal of vitamin K antagonist therapy in this population. 
© 2018 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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Vitamin K antagonists (VKAs) are frequently prescribed for the
revention and treatment of thromboembolic events (TEEs). Bleed-
ng events are a known risk of anticoagulation therapy—annually,
pproximately 1% to 7% of VKA-treated patients in Western coun-
ries 1,2 and 6.6% of VKA-treated Japanese patients experience major✩ ClinicalTrials.gov identiﬁer: NCT02281201. ( Curr Ther Res Clin Exp . 2018; 
9:XXX–XXX) 
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011-393X/© 2018 The Authors. Published by Elsevier Inc. This is an open access article uleeding. 3 In cases of major bleeding or need for urgent surgery,
hese patients require rapid VKA reversal. 
Nonactivated 4-factor prothrombin complex concentrates (4F- 
CCs) have long been approved and recommended in Europe
or urgent VKA reversal 4–6 ; and based on results from 2 large,
ultinational randomized controlled trials (RCTs) (primarily US 
nd European sites) evaluating 4F-PCC use for urgent VKA reversal
n patients with acute major bleeding 7 or needing urgent surgical
ntervention, 8 a 4F-PCC (Kcentra; CSL Behring, Marburg, Germany)
as also approved in the United States. During March 2017, the
ame 4F-PCC was approved in Japan based on this global clinical
rogram and the results of a Phase IIIb study in Japanese patients. 9 nder the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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g  Pharmacokinetic (PK) analyses in speciﬁc ethnicities are an
mportant consideration for the licensing of new medicines 10 
ecause ethnicity and genetic variability may inﬂuence the PK
roﬁle of a medicine and also individual response to therapies.
n particular, PK proﬁles are known to differ between global and
apanese populations and studies have demonstrated that in some
ases lower doses administered in Japanese populations lead to
imilar drug exposure, eﬃcacy, and safety proﬁles as seen in global
opulations. 11–13 Furthermore, current guidelines for patients with
onvalvular atrial ﬁbrilliation taking VKAs recommend different
herapeutic international normalized ratio (INR) ranges in different
egions, with US guidelines recommending an INR of 2.0 to 3.0 for
ll patients, 14 and Japanese guidelines recommending an INR of
.0 to 3.0 for patients younger than age 70 years but 1.6 to 2.6 in
hose aged 70 years or older. 15 
This short report discusses the effect of 4F-PCC infusion on the
lasma levels of the vitamin K-dependent coagulation factors and
roteins C and S in VKA-anticoagulated Japanese patients requiring
apid reversal of anticoagulation before an urgent surgical/invasive
rocedure or due to acute major bleeding. 
ethods 
This was a subanalysis of a prospective, open-label, single-arm
hase IIIb study (ClinicalTrials.gov identiﬁer: NCT02281201) con-
ucted in Japan (November 2014–March 2016). Written informed
onsent was obtained from all patients (or their legally autho-
ized representatives). The study was sponsored by CSL Behring,
pproved by the independent ethics committees of the participat-
ng centers, and performed in accordance with local ethical and
egal requirements; written informed consent was obtained from
ll patients (or legally authorized representatives). 
The methods of the study, including study design, treatment al-
ocation, and inclusion/exclusion criteria, have been described in
etail elsewhere. 9 Brieﬂy, VKA-treated Japanese patients present-
ng with an INR ≥ 2.0 and requiring rapid anticoagulation rever-
al for either an acute major bleeding event (bleeding group) or
efore an urgent surgical/invasive procedure (surgical group) were
nrolled. Patients received 4F-PCC (Beriplex; CSL Behring, Marburg,
ermany); also marketed as Kcentra, dosed according to baseline
NR and bodyweight (INR between ≥ 2.0 and < 4.0, 25 IU/kg, INR
etween ≥ 4.0 and ≤ 6.0, 35 IU/kg, and INR > 6.0, 50 IU/kg), and
oncomitant vitamin K was administered according to local prac-
ice. 
The plasma activity levels of factors II, VII, IX, X, and proteins C
nd S were measured at the same points in time as the multina-
ional RCTs by Goldstein et al 8 and Sarode et al, 7 namely, within 3
ours before the start of 4F-PCC infusion and 0.5, 1, 3, 6, 12, and 24
ours following the end of infusion. Blood collection and sample
reparation was performed at each site according to their speciﬁed
tandards. In brief, 4.5 mL blood was drawn into a sodium citrate
ube, inverted gently 3 to 4 times and centrifuged for 15 minutes
t 40 0 0 to 50 0 0 rpm. The plasma was transferred into a 3.6 mL
ransfer tube and centrifuged again for 15 minutes at 40 0 0 to 50 0 0
pm. Plasma samples (1 mL) were then extracted, transported to
he central laboratory, and stored at –70 °C until analysis, where
hey were thawed in a water bath at 37 °C. Analysis of the coag-
lation factors was performed using 1-stage clotting assays with
ommercially available reagents (Thromborel S and Pathromtin SL)
urchased from Siemens Healthineers, Erlangen, Germany. Deter-
ination of protein C and S was performed with Berichrom Pro-
ein C and Innovance Protein S assays (Siemens Healthineers). All
ssays were processed on a BCS device (Siemens Healthineers) cal-
brated against standard human plasma. 
Factor levels (activity) were summarized by descriptive statis-
ics, as described previously. 9 C max was observed as maximumlasma level and AUC last was area under the curve from the
eginning of infusion to the last measurable plasma level using
he actual sampling times. All values were baseline corrected. The
lassical and incremental in vivo recovery (IVR) were determined
or each coagulation factor and for proteins C and S. Classical
VR (%) was calculated as follows: 100 × (actual increase) / (ex-
ected increase). Incremental IVR (IU/dL) / (IU/kg) was calculated
s follows: (IU/dL activity rise in plasma) / (IU/kg body weight
nfused). All data analysis was performed using SAS version 9.3
SAS Institute Inc, Cary, North Carolina). 
Adverse events (AEs) and serious AEs were recorded up to Day
4 and Day 45, respectively. 
esults 
atients 
In total, 11 patients were enrolled in the study: 6 in the bleed-
ng group and 5 in the surgical group; all patients completed the
tudy ( Fig. 1 ). The 11 patients enrolled are the same patients pre-
iously described: median (range) age was 87 years (53–92 years)
nd 78 years (61–91 years) in the bleeding and surgical groups,
espectively, whereas the median (range) INR at baseline was 4.76
2.26–10.56) and 3.13 (2.11–5.82), respectively. 9 Both groups had
 median weight of 60 kg (bleeding group range = 46–73 kg and
urgical group range = 31–70 kg). 9 
The median (range) dose of 4F-PCC administered was 2250 IU
1150–3650 IU) in the bleeding group and 1500 IU (1085–1750 IU)
n the surgical group. A dose of 25 IU/kg and 50 IU/kg was ad-
inistered in 3 patients each in the bleeding group, and 4 patients
eceived a dose of 25 IU/kg and 1 received a dose of 50 IU/kg in
he surgical group. Nine patients received intravenous vitamin K
range = 10–20 mg) within 24 hours of 4F-PCC infusion and 2 pa-
ients, both in the bleeding group, were not administered any vi-
amin K. Further details of patient characteristics and dosing are
escribed elsewhere. 9 
NR reduction and hemostatic eﬃcacy 
Eﬃcacy results have been presented in full elsewhere. 9 Brieﬂy,
0 minutes after infusion end, INR reduction to ≤ 1.3 was achieved
n 83% and 80% of patients in the bleeding and surgical groups,
espectively. This achievement of target INR was maintained over
4 hours in both the bleeding and surgical groups ( Fig. 2 ). Effec-
ive hemostasis (as evaluated by the treating physician using pre-
eﬁned rating criteria [excellent or good, and very good or sat-
sfactory in the bleeding and surgical groups, respectively]) was
chieved in 60% and 100% of evaluable patients in the bleeding and
urgical groups, respectively. 9 
oagulation factor and protein C and S plasma levels 
Following 4F-PCC infusion, rapid increases in plasma concen-
rations of all vitamin K-dependent coagulation factors, and pro-
eins C and S were seen in both groups. Compared with baseline,
he median concentrations of all coagulation factors and proteins
 and S, were increased at 30 minutes after the end of the 4F-
CC infusion by at least 100% and 70% in the bleeding and surgical
roups, respectively. Median values 30 minutes after infusion end
nd the numerical change from baseline are shown in Table 1 . This
ncrease was consistent irrespective of an individual’s baseline INR
cross both groups, and median plasma levels were within normal
eference ranges 30 minutes after infusion end in both groups for
actors II, IX, and X, and proteins C and S ( Table 1 ). An increase
n median factor VII levels was seen in both groups but neither
roup reached normal reference ranges 30 minutes after infusion
M. Yasaka et al. / Current Therapeutic Research 89 (2018) 21–26 23 
T
a
b
le
 
1
 
M
e
d
ia
n
 
p
la
sm
a
 
le
v
e
ls
 
a
n
d
 
p
h
a
rm
a
co
k
in
e
ti
c 
p
ro
ﬁ
le
 
o
f 
co
a
g
u
la
ti
o
n
 
fa
ct
o
rs
 
a
n
d
 
p
ro
te
in
 
C
 
a
n
d
 
S
. ∗
N
o
rm
a
l 
ra
n
g
e
, 
%
 
n
o
rm
a
l 
B
le
e
d
in
g
 
g
ro
u
p
 
S
u
rg
ic
a
l 
g
ro
u
p
 
B
a
se
li
n
e
, 
%
 
n
o
rm
a
l 
3
0
 
m
in
 
a
ft
e
r 
in
fu
si
o
n
 
e
n
d
, 
%
 
n
o
rm
a
l 
C
h
a
n
g
e
 
fr
o
m
 
b
a
se
li
n
e
, 
%
 
n
o
rm
a
l 
A
U
C
 la
st
 
C
 m
a
x
 
B
a
se
li
n
e
, 
%
 
n
o
rm
a
l 
3
0
 
m
in
 
a
ft
e
r 
in
fu
si
o
n
 
e
n
d
, 
%
 
n
o
rm
a
l 
C
h
a
n
g
e
 
fr
o
m
 
b
a
se
li
n
e
, 
%
 
n
o
rm
a
l 
A
U
C
 la
st
 
C
 m
a
x
 
Fa
ct
o
r 
II
 
7
0
–
1
2
0
 
2
0
.2
 
8
7.
2
 
6
2
.0
 
11
6
8
.9
 
6
8
.5
 
3
2
.5
 
7
1.
1
 
3
8
.6
 
8
7
9
.4
 
(4
2
0
.0
 
4
0
.0
 
(0
.0
 
to
 
3
4
.9
) 
(5
4
.7
 
to
 
1
0
8
.3
) 
(2
9
.7
 
to
 
1
0
8
.3
) 
(7
8
3
.3
 
to
 
2
1
6
4
.4
) 
(4
5
.2
 
to
 
11
0
.8
) 
(1
8
.3
 
to
 
3
9
.5
) 
(5
6
.0
–
11
4
.1
) 
(3
2
.9
–
7
4
.6
) 
to
 
17
0
0
.8
) 
(3
2
.9
 
to
 
8
1.
3
) 
Fa
ct
o
r 
V
II
 
7
0
–
1
2
0
 
1
6
.2
 
5
1.
9
 
3
1.
8
 
8
9
5
.6
 
(4
9
8
.6
 
5
4
.0
 
2
8
.2
 
4
4
.8
 
2
1.
7
 
9
3
7.
7
 
(2
4
6
.8
 
4
3
.0
 
(8
.4
 
to
 
3
9
.0
) 
(3
8
.9
 
to
 
8
4
.2
) 
(–
0
.1
 
to
 
7
5
.4
) 
to
 
1
8
2
6
.6
) 
(3
6
.5
 
to
 
8
9
.3
) 
(9
.0
 
to
 
4
1.
9
) 
(2
4
.8
–
8
7.
8
) 
(1
5
.8
–
4
5
.9
) 
to
 
1
4
0
2
.8
) 
(1
8
.0
 
to
 
6
4
.8
) 
Fa
ct
o
r 
IX
 
7
0
–
1
2
0
 
3
1.
1
 
7
9
.2
 
4
1.
9
 
8
6
1.
0
 
(1
7
3
.0
 
5
3
.7
 
5
0
.5
 
7
8
.2
 
3
0
.5
 
9
2
9
.6
 
(1
4
6
.0
 
5
4
.0
 
(9
.9
 
to
 
4
9
.0
) 
(4
9
.7
 
to
 
9
2
.7
) 
(7
.8
 
to
 
8
2
.8
) 
to
 
2
2
5
4
.5
) 
(3
4
.1
 
to
 
11
8
.7
) 
(2
4
.2
 
to
 
6
3
.9
) 
(4
2
.2
 
to
 
1
0
4
.4
) 
(1
4
.3
 
to
 
4
9
.0
) 
to
 
17
1
6
.3
) 
(1
5
.8
 
to
 
1
0
9
.4
) 
Fa
ct
o
r 
X
 
7
0
–
1
2
0
 
1
0
.0
 
1
0
3
.4
 
8
8
.4
 
1
6
5
6
.1
 
9
3
.9
 
2
1.
3
 
7
6
.9
 
5
5
.6
 
1
4
8
5
.0
 
6
9
.2
 
(5
.6
 
to
 
2
2
.0
) 
(5
5
.8
 
to
 
1
3
8
.2
) 
(4
4
.2
 
to
 
1
3
2
.6
) 
(1
1
3
0
.4
 
to
 
2
4
6
7.
0
) 
(6
1.
4
 
to
 
1
3
2
.6
) 
(8
.0
 
to
 
2
4
.9
) 
(5
8
.9
 
to
 
1
2
9
.1
) 
(5
0
.9
 
to
 
1
0
4
.2
) 
(8
2
1.
7
 
to
 
2
2
6
6
.8
) 
(5
0
.9
 
to
 
1
0
4
.2
) 
P
ro
te
in
 
C
 
7
0
–
1
4
0
 
3
8
.4
 
11
6
.0
 
7
7.
5
 
1
2
7
8
.8
 
8
6
.6
 
4
4
.2
 
9
9
.3
 
4
3
.7
 
9
4
0
.2
 
(3
8
1.
4
 
4
3
.7
 
(2
3
.5
 
to
 
5
2
.5
) 
(6
8
.4
–
1
3
9
.0
) 
(1
9
.0
 
to
 
11
0
.1
) 
(8
6
3
.9
 
to
 
2
2
2
3
.0
) 
(5
6
.9
 
to
 
11
0
.1
) 
(1
9
.6
 
to
 
5
5
.6
) 
(5
9
.7
 
to
 
1
4
4
.2
) 
(4
0
.1
 
to
 
9
4
.9
) 
to
 
1
9
2
0
.6
) 
(4
0
.1
 
to
 
9
6
.6
) 
P
ro
te
in
 
S
 
6
0
–
1
3
9
 
3
7.
1
 
9
1.
6
 
5
4
.7
 
8
2
9
.6
 
(5
3
9
.7
 
6
6
.2
 
3
9
.4
 
7
7.
8
 
3
4
.8
 
6
5
7.
3
 
(3
4
4
.9
 
3
4
.8
 
(2
1.
8
 
to
 
4
6
.5
) 
(4
5
.9
 
to
 
11
0
.7
) 
(9
.6
 
to
 
7
5
.7
) 
to
 
1
4
7
3
.3
) 
(3
7.
3
 
to
 
8
6
.6
) 
(2
3
.2
 
to
 
5
4
.5
) 
(6
2
.6
 
to
 
1
0
9
.2
) 
(3
2
.3
 
to
 
6
9
.8
) 
to
 
1
3
1
0
.6
) 
(3
2
.3
 
to
 
7
5
.4
) 
∗
D
a
ta
 
a
re
 
p
re
se
n
te
d
 
a
s 
m
e
d
ia
n
 
(m
in
im
u
m
–
m
a
x
im
u
m
).
 
C
h
a
n
g
e
 
fr
o
m
 
b
a
se
li
n
e
 
w
a
s 
ca
lc
u
la
te
d
 
b
a
se
d
 
o
n
 
th
e
 
in
d
iv
id
u
a
l 
p
a
ti
e
n
t 
ch
a
n
g
e
 
a
n
d
 
n
o
t 
th
e
 
m
e
d
ia
n
 
v
a
lu
e
s.
 
e  
p
 
c  
b  
f
 
v  
C  
4  
m  
a
 
p  
i  
u  
s  
p  
e  
a  
t  
a  
r
 
r  
v
t
I
a
 
b  
t  
i  
(  
t  
g
S
 
t  
i  
T  
s  
b  
f  
t  
t
D
 
l  
s  
A  
i  
w  
t  
t  
o  
v  
t  
c  
c  nd ( Table 1 ). The AUC and C max for each coagulation factor and
rotein are also shown in Table 1 . 
Following the initial rapid increase, median plasma levels of all
oagulation factors and proteins C and S remained elevated from
aseline, and within physiologic levels, for at least 24 hours postin-
usion in both the bleeding and surgical groups ( Fig. 2 ). 
Two patients in the bleeding group did not receive concomitant
itamin K. Overall, lower levels of coagulation factors and proteins
 and S were observed in these patients at 12 and 24 hours after
F-PCC administration compared with patients who received vita-
in K. One of these patients maintained an INR ≤ 1.3 at 12 hours,
lthough the other patient had a 12-hour INR of 2.68. 
Plasma activity levels of a coagulation factor exceeded the up-
er limit of normal (ULN) in 3 patients. In 1 patient in the bleed-
ng group, plasma levels of factor X were above the ULN 30 min-
tes after infusion; this patient did not experience any AEs. In the
urgical group, 2 patients had plasma levels above the ULN. One
atient had increases of factors II, VII, and X, and protein C at sev-
ral points in time; this patient was diagnosed with a left atrial
ppendage thrombus 3 days after receiving 4F-PCC. The second pa-
ient had a level of factor VII exceeding the normal range 24 hours
fter infusion end; this patient did not experience any TEEs or se-
ious AEs. 
Overall, administration of 4F-PCC in VKA-treated patients expe-
iencing acute bleeding or needing urgent surgery rapidly raised
itamin K-dependent coagulation factors without producing sus- 
ained supraphysiologic levels. 
n vivo recovery and response of coagulation factors and proteins C 
nd S 
The median classical IVR ranged from 44.6% to 102.2% in the
leeding group and 54.1% to 130.7% in the surgical group, whereas
he median incremental IVR (response) varied from 1.136 to 2.2554
n the bleeding group and 0.868 to 2.262 in the surgical group
 Table 2 ). In line with the change from baseline at 30 minutes, fac-
or VII had the lowest median classical and incremental IVR in both
roups, whereas the highest were seen with factor X. 
afety proﬁle 
4F-PCC infusion was well tolerated in both groups with no pa-
ients discontinuing treatment or withdrawing from the study ow-
ng to an AE. 9 Two patients in the surgical group experienced a
EE (left atrial appendage thrombosis on Day 3 in 1 patient and
plenic infarction on Day 2 in the other). Both events were classed
y investigators as related to 4F-PCC use and of mild severity, and
urther follow-up was not deemed necessary. No relationship be-
ween TEEs and elevated plasma levels of any individual coagula-
ion factor was identiﬁed in this study. 
iscussion 
As expected, the baseline levels of coagulation factors were
ower in the bleeding group than the surgical group, which is con-
istent with the higher baseline INR seen in the bleeding group.
dministration of 4F-PCC resulted in rapid and sustained increases
n the plasma levels of coagulation factors and proteins C and S,
ithout exceeding normal reference levels in the majority of pa-
ients. The slower increase in factor VII levels in comparison with
he other coagulation factors is likely a result of the lower content
f factor VII in 4F-PCC, with endogenous production stimulated by
itamin K responsible for the continued increase after 8 hours. Fur-
hermore, factor VII binds with tissue factor at the start of the
oagulation cascade, 16 and this earlier consumption of this factor
ompared with the other coagulation factors may explain the more
24 M. Yasaka et al. / Current Therapeutic Research 89 (2018) 21–26 
Fig. 1. Consolidated standards of reporting trials diagram. 
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rradual increase in plasma levels seen with factor VII. Overall, the
ncreases in factor levels correlated well with the rapid reduction
n patients’ INR and achievement of hemostasis following 4F-PCC
nfusion. 9 
These results are consistent with those seen in the 2 large,
ultinational RCTs that evaluated 4F-PCC use for urgent VKA re-
ersal in patients with acute major bleeding 7 or before an urgent
urgical/invasive procedure. 8 As with the results presented here,
F-PCC administration resulted in a rapid increase from baseline
n plasma levels of the coagulation factors and proteins C and S,
hich remained elevated over the following 24 hours. 7,8 
Concomitant vitamin K administration with PCC is important to
void patients experiencing an increase in INR after 12 hours, as
ighlighted by the reduced coagulation factor and proteins C and S
lasma levels and elevated 12-hour INR seen in those patients who
id not receive vitamin K. No speciﬁc tolerability concerns were identiﬁed in this Japanese
opulation, with a safety proﬁle consistent to that seen in the
arge, multinational RCTs. 7,8 Of note, no relationship between co-
gulation factor levels and risk of TEE development was identiﬁed
n this study. This ﬁnding was also shown in an integrated anal-
sis of the 2 multinational RCTs, which demonstrated no notable
ifference between median factor levels in patients with or with-
ut TEEs, and concluded that the levels of coagulation factors may
ot have a major role in determining the occurrence of TEEs. 17 In-
erent risk factors and delayed reanticoagulation may be more im-
ortant contributors to TEE risk; reversing anticoagulation restores
he underlying thrombotic risk that required anticoagulation in the
rst place; therefore, restarting anticoagulation should be restarted
henever possible as soon as the risk of thrombosis outweighs the
isk of further bleeding. 
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Fig. 2. International normalized ratio (INR) values and plasma levels of coagulation factors and proteins C and S over 24 hours. Data are presented as median for INR and 
median (range) for plasma levels. 
Table 2 
Classical and incremental in vivo response (IVR). ∗
Bleeding group Surgical group 
Classical IVR † Incremental IVR ‡ Classical IVR † Incremental IVR ‡ 
Factor II 80.7 1.961 85.6 1.554 
(63.6–121.1) (1.501–2.308) (48.0–124.7) (0.940–2.963) 
Factor VII 44.6 1.136 54.1 0.868 
(31.1–84.3) (0.735–11.508) (23.0–78.7) (0.451–1.823) 
Factor IX 60.5 1.478 67.1 1.220 
(42.6–92.6) (1.004–1.976) (26.0–83.8) (1.454–4.138) 
Factor X 102.2 2.554 130.7 2.262 
(91.2–148.2) (2.102–3.100) (74.2–159.9) (1.454–4.138) 
Protein C 90.7 2.1199 105.5 1.759 
(81.8–123.1) (1.899–2.556) (58.5–139.3) (1.146–3.769) 
Protein S 65.7 1.503 84.3 1.4010 
(60.3–84.6) (1.452–1.808) (47.1–102.5) (0.923–2.772) 
∗ Data are presented as median (minimum–maximum). 
† Classical IVR (%) = 100 × (actual increase)/(expected increase). 
‡ Incremental IVR [(IU/dL)/(IU/kg)] = (IU/dL activity rise in plasma)/(IU/kg body weight infused). 
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a  Limitations of this study include the small number of patients
nrolled and the lack of a comparator group and as such these re-
ults should be interpreted with caution. 
onclusions 
4F-PCC infusion resulted in rapid increases in coagulation factor
evels in patients requiring urgent VKA reversal, without reaching
upraphysiologic levels and were in line with the decrease seen
n INR within 30 minutes after the end of infusion. These results
re consistent with the results seen in the pivotal multinational
CTs 7,8 and indicate that the 4F-PCC dosing regimen used in Eu- 
ope and the United States is appropriate in Japanese patients. 4F-
CC has a favorable safety proﬁle and is an effective therapeuticption for urgent reversal of VKA therapy in Japanese patients pre-
enting with major bleeding or requiring urgent surgery. 
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